2E9 Stock Chart & Stats
€0.05
€0.00(0.00%)
At close: 4:00 PM EST
€0.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.11
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€39.94M
Enterprise Value€301.20M
Total Cash (Recent Filing)€145.63M
Total Debt (Recent Filing)€357.00K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 20, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€1.44M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a substantial equity base provide durable financial flexibility. This cushion supports ongoing R&D, commercialization and potential regulatory or market setbacks without immediate solvency pressure, enabling longer-term execution on vaccine rollouts and partnerships.
Commercial Product Revenue StreamHaving an approved, commercial vaccine (Strangvac) and established distribution partners is a structural advantage versus pre-commercial peers. It provides a recurring revenue base, market validation of the technology, and a platform for geographic expansion, licensing or further product launches.
Improving Free Cash Flow TrendA material (~48%) improvement in free cash flow signals operational progress or better conversion of sales into cash. While still negative, this trend reduces the speed of capital depletion, improves runway durability, and if continued supports a transition toward self-funding operations or less dilutive financing.
Bears Say
Heavy Cash BurnSustained, large negative operating and free cash flows materially shorten runway and force reliance on external financing or partner milestone payments. Over months this increases dilution risk, constrains strategic options, and can divert management focus from commercialization to capital raising.
Deep Operating Losses And Negative MarginsExtremely negative gross and operating margins indicate unit economics are currently unprofitable; this is structural unless production costs fall or pricing/adoption meaningfully improves. Persistent losses erode equity and limit reinvestment capacity, impacting long-term viability without corrective action.
Modest And Declining Revenue BaseA small, contracting revenue base constrains operating leverage and makes fixed-cost absorption difficult. Declining sales undermine commercial momentum and raise questions about market penetration and pricing power in approved markets, slowing a path to sustainable profitability.
Intervacc AB News
2E9 FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was €0.01 and its highest was €0.11 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is €39.94M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Aug 20, 2026 which is in 40 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on May 13, 2026. The company reported -€0.005 earnings per share for the quarter, the consensus estimate of -€0.005 by €0.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is >-0.01.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -€0.005 in its last earnings report, expectations of -€0.005. Following the earnings report the stock price went down -6.494%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in DE:2E9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―